Inclusion Criteria:  Aged ≥18 years at the start of treatment of AML with Vyxeos liposomal Pathological diagnosis of t-AML or AML-MRC according to World Health Organization criteria (with at least 20% blasts in the peripheral blood or bone marrow) Patient has received at least one infusion of Vyxeos liposomal, prescribed as per the SmPC Patient signs an informed consent form or is included in accordance with an informed consent waiver  Exclusion Criteria:  Treatment with Vyxeos liposomal as part of a clinical trial or managed access program Prior treatment intended for induction therapy of AML; only hydroxyurea is permitted for control of blood counts